

Change Notification for the UK Blood Transfusion Services

Date of Issue: 13 October 2025

Implementation: to be determined by each Service

No. 19 – 2025


Infertility

This notification includes the following changes:

	BM-DSG Bone Marrow & Peripheral Blood Stem Cell	CB-DSG Cord Blood	GDRI Geographical Disease Risk Index	TD-DSG Tissue – Deceased Donors	TL-DSG Tissue – Live Donors	WB-DSG Whole Blood & Components	Red Book Guidelines for the BTS in the UK
1. Infertility	☐	☐	☐	☒	☐	☐	☐
2. Infertility	☐	☐	☐	☐	☒	☐	☐
3. Changes to the A-Z index	☐	☐	☐	☒	☒	☐	☐



Dr Richard Lomas
Chair, Standing Advisory Committee on Tissues (SACT)



Dr Stephen Thomas
Professional Director of JPAC

Changes are indicated using the key below. This formatting will not appear in the final entry.

original text	«inserted text»	deleted text
---------------	-----------------	-------------------------

1. Changes apply to the **Tissues – Deceased Donors DSG**

Infertility

(revised entry)

<i>Obligatory</i>	Must not donate if: a) Has ever been given human gonadotrophin of pituitary origin. b) If «the» donor «is known to» knows that they have ever been treated with Metrodin HP®.
<i>Discretionary</i>	If treated exclusively with non-pituitary derived gonadotrophins, accept.
<i>See if Relevant</i>	«Hormone Replacement and Sex Hormone Therapy» <u>Prion Associated Diseases</u>
<i>Additional Information</i>	The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy. «Donors who have undergone egg donation, egg collection for fertility preservation, and surgical sperm retrieval should be assessed regarding any hormone treatment they have received.» There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD. Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.
<i>Reason for Change</i>	«To update 'Additional Information' section by removing the section regarding a 12-week safeguarding time from treatment, and inclusion of additional information regarding any hormone treatment received. Amendment of wording in the 'Obligatory' section to reflect this entry relates to deceased donors Addition of link to 'Hormone Replacement and Sex Hormone Therapy' entry.» To update the 'additional information' section with a statement that there is no evidence that transplantation of eggs or embryos might lead to spread of vCJD.

2. Changes apply to the **Tissues – Live Donors DSG**

Infertility

(revised entry)

<i>Obligatory</i>	Must not donate if: a) Has ever been given human gonadotrophin of pituitary origin. b) If donor knows that they have ever been treated with Metrodin HP®.
<i>Discretionary</i>	If treated exclusively with non-pituitary derived gonadotrophins, accept.
<i>See if Relevant</i>	«Hormone Replacement and Sex Hormone Therapy» <u>Prion Associated Diseases</u>
<i>Additional Information</i>	The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy. «Donors who have undergone egg donation, egg collection for fertility preservation, and surgical sperm retrieval should be assessed regarding any hormone treatment they have received.» There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD. Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.
<i>Reason for Change</i>	«To update 'Additional Information' section by removing the section regarding a 12-week safeguarding time from treatment, and inclusion of additional information regarding any hormone treatment received. Addition of link to 'Hormone Replacement and Sex Hormone Therapy' entry.» To update the 'additional information' section with a statement that there is no evidence that transplantation of eggs or embryos might lead to spread of vCJD.

3. Changes apply to both **Tissues (Deceased and Live Donors) DSGs**

The following redirection will be added to the **A-Z index**

Fertility » Infertility